VIVA: TAVR vs. SAVR in Patients With Severe AS and Small Aortic Annulus?

Results from the VIVA trial comparing hemodynamic and clinical outcomes between TAVR and surgical aortic valve replacement (SAVR) in patients with severe aortic stenosis (AS) and small aortic annulus (SAA) provide important insights into how best to treat this patient population. The findings presented during TCT 2023 and simultaneously published in Circulation show both TAVR and SAVR to be "valid alternatives."

WATCH-TAVR: Concomitant TAVR and LAAO Shown Noninferior to TAVR Plus Medical Therapy

A strategy involving left atrial appendage occlusion (LAAO) at the same time as TAVR was noninferior to TAVR plus medical therapy for the primary composite endpoint of all-cause mortality, all stroke, and life-threatening and major bleeding in patients with severe aortic stenosis and atrial fibrillation (AFib), based on findings from the WATCH-TAVR trial presented during TCT 2023 and simultaneously published in Circulation.

PARTNER 3: New Studies Shed Light on Long-Term Outcomes of TAVR vs. SAVR in Low-Risk Patients With Severe AS

There was no significant between-group difference in the composite of death, stroke or rehospitalization at five years in patients who were at low surgical risk with severe, symptomatic aortic stenosis (AS) who underwent either TAVR or surgical aortic valve replacement (SAVR), based on new findings from the PARTNER 3 trial presented during TCT 2023 and simultaneously published in the New England Journal of Medicine. Similarly, no significant differences were observed in the hierarchical composite that included death, disabling stroke, nondisabling stroke and the number of rehospitalization days.